Liraglutide vs Retatrutide

Liraglutide is a GLP-1 receptor agonist already approved by the FDA and sold under the brand names Saxenda and Victoza, used to treat type 2 diabetes, obesity, and reduce cardiovascular risk. Retatrutide is an experimental drug that works on three different receptors (GIP, GLP-1, and glucagon) and is not yet FDA-approved for any condition.

AI summary of the sources below.